Role of PPARs in Liver Disease and Endothelial Dysfunction
Author Information
Author(s): Madariaga Traconis Ana Paula, Uribe-Esquivel Misael, Barbero Becerra Varenka Julieta
Primary Institution: Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico
Hypothesis
Are peroxisome proliferator-activated receptors (PPARs) potential regulators of metabolism and inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD)?
Conclusion
PPARs, especially PPARĪ±, are promising therapeutic targets for managing MASLD and its associated vascular complications.
Supporting Evidence
- PPAR agonists have shown promise in improving metabolic and cardiovascular health in patients with MASLD.
- Endothelial dysfunction is a key factor in the progression of MASLD and cardiovascular diseases.
- Clinical trials are ongoing to explore the efficacy of PPAR agonists in treating MASLD.
Takeaway
This study looks at how certain proteins called PPARs can help treat liver disease and improve blood vessel health.
Methodology
This review synthesizes existing research on PPARs and their effects on endothelial dysfunction and MASLD.
Limitations
Some studies did not explore potential adverse effects of PPAR agonists, and small sample sizes may limit the findings.
Statistical Information
Confidence Interval
95%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website